Juhani Anttila - Actelion Member of the Board of Directors

Director

Mr. Juhani Anttila was Member of the Board of Directors of Actelion Ltd since 2005. He is Member of the Finance and Audit Committee of the Company. He was Managing Partner at CA Corporationrationrate Advisers from 1981 till 1985. He served as Managing Director of Nokia GmbH from 1985 to 1988. Between 1989 and 1995 he served as Member of the Executive Board of Nokia Consumer Electronics Division. He acted as Chairman of the Executive Board of Nokia GmbH from 1990 till 1995. Afterwards he held the position of President and Chief Executive Officer of the Swisslog Holding Ltd from 1996 until 2002. He served as Chief Executive Officer of Ascom Holding Ltd from 2003 till 2004. Since 2005 he was Managing Partner of ValCrea AG. He is also Chairman of the Board of Directors of Ascom Holding Ltd. He holds a Masters degree, obtained in 1978, and a Bachelors degree, obtained in 1976, in Law from the Helsingin yliopisto. since 2005.
Age 62
Tenure 19 years
Phone41 61 565 65 65
Webhttp://www.actelion.com

Actelion Management Efficiency

The company has return on total asset (ROA) of 23.87 % which means that it generated a profit of $23.87 on every $100 spent on assets. This is very large. Similarly, it shows a return on equity (ROE) of 47.08 %, meaning that it generated $47.08 on every $100 dollars invested by stockholders. Actelion's management efficiency ratios could be used to measure how well Actelion manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

DIRECTOR Age

Jon MarshallNoble plc
68
Anna ManzDiageo PLC ADR
42
Glyn BarkerTransocean
67
Samuel HathornNational Beverage Corp
73
Douglas DafoeAKITA Drilling
60
Ek TanTransocean
71
Leanne WoodDiageo PLC ADR
41
Martin McNamaraTransocean
68
Susan KilsbyDiageo PLC ADR
62
Julie EdwardsNoble plc
62
Kathryn MikellsDiageo PLC ADR
54
Peggy BruzeliusDiageo PLC ADR
69
Vanessa ChangTransocean
67
Lavanya ChandrashekarDiageo PLC ADR
52
Ireena VittalDiageo PLC ADR
51
Colby RollinsCrimson Wine
42
Cecil ConleeNational Beverage Corp
80
Ashley AlmanzaNoble plc
53
Margareth OvrumTransocean
62
Roger JenkinsNoble plc
59
Francesca SchulerCrimson Wine
47
Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes low molecular weight drugs for unmet medical needs. The company was founded in 1997 and is headquartered in Allschwil, Switzerland. Actelion Ltd is traded on OTC Market in USA. Actelion Ltd UNSP [ALIOY] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Actelion UNSP Leadership Team

Elected by the shareholders, the Actelion's board of directors comprises two types of representatives: Actelion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Actelion. The board's role is to monitor Actelion's management team and ensure that shareholders' interests are well served. Actelion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Actelion's outside directors are responsible for providing unbiased perspectives on the board's policies.
Rudi Frank, Senior Vice President Head Global Quality Management, Member of the Extended Executive Committee
Marian Borovsky, Senior Vice President Group General Counsel, Member of the Extended Executive Committee, Corporate Secretary to the Board of Directors
Thomas Widman, Co-Founder
Nicholas Franco, Executive Vice President Chief Business Development Officer, Member of the Executive Committee
Christian Albrich, Senior Vice President Head Global Human Resources and a member of the Extended Actelion Executive Committee
Martine Clozel, Senior Vice President Chief Scientific Officer, Head of Drug Discovery, Pharmacology & Preclinical Development, Member of the Extended Executive Committee
Robert Bertolini, Member of the Board of Directors
Juhani Anttila, Member of the Board of Directors
JeanPierre Garnier, Chairman of the Board of Directors
David Stout, Member of the Board of Directors
JeanPaul Clozel, CEO, Member of the Executive Committee, Delegate of the Board of Directors
Guy Braunstein, Executive Vice President Head of Global Clinical Development, Member of the Executive Committee
Herna Verhagen, Member of the Board of Directors
Andrew Weiss, Senior Vice President Head Investor Relations and Corporate Communications, Member of the Extended Executive Committee
Michael Jacobi, Member of the Board of Directors
Jean Malo, Member of the Board of Directors
Otto Schwarz, COO, Executive Vice President Member of the Executive Committee
Andre Muller, CFO, Executive Vice President Member of the Executive Committee
Peter Gruss, Member of the Board of Directors
John Greisch, Member of the Board of Directors

Actelion Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Actelion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Actelion in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Actelion's short interest history, or implied volatility extrapolated from Actelion options trading.

Pair Trading with Actelion

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Actelion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Actelion will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Exelon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exelon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exelon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exelon to buy it.
The correlation of Exelon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exelon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exelon moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exelon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in Actelion Pink Sheet

If you are still planning to invest in Actelion UNSP check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Actelion's history and understand the potential risks before investing.
Commodity Directory
Find actively traded commodities issued by global exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Equity Valuation
Check real value of public entities based on technical and fundamental data
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance